TLC Therapeutics

Specialty pharma offering little risk with an attractive near-term ROI

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Baltimore, MD, US
  • Currency USD
  • Founded July 2016
  • Employees 2
  • Incorporation Type LLC

Company Summary

Low-risk, near-to-market specialty pharma company with oral liquid CNS products, obtained via a licensing & supply agreement with Perrigo.

Confirmed FDA requirements to submit a 505(b)(2) NDA for TLC-100 (lead product). TLC-100 is first and only liquid formulation of former $6B brand. NDA filing = Q4 2018.

Currently seeking a $3 - 3.5M A Round with the potential to provide near-term return through strategic partnership on TLC-100.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free